Andreas Aslund
Cell and gene therapies are seen as the next frontier in medicine as they have the potential to bring cures to patients that suffer from life-threatening diseases without many treatment options available to them. The idea that a patient’s own cells can be reprogrammed to replace or eliminate faulty genes or to attack cancer cells in a way that is not naturally possible is giving hope to many. In 2017, we have seen several approvals from these innovative medicines, Kymriah, Yescarta and Luxturna to name a few. However, a key challenge for all players and drug-makers in this field remains to be addressed: The cost of manufacturing is critically high due to the nature of these highly personalized medicines.
English 
Spanish 
Chinese 
Russian 
German 
French 
Portuguese 
Hindi